Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GDUFA: How Much Does FDA Know About U.S. Generic Market After Facility Self-Identification?

This article was originally published in The Gold Sheet

Executive Summary

FDA continues to analyze facility data following generic drug facility fee announcement; some fees were higher than anticipated after fewer manufacturing plants registered than expected. But industry believes the count is accurate and illustrates the influence of foreign manufacturers.

Advertisement

Related Content

US FDA Changes Data Source For GDUFA II Facility Fee Setting
US FDA Changes Data Source For GDUFA II Facility Fee Setting
GDUFA Self-Identification Woes Can’t Deflate Industry, FDA Enthusiasm
FDASIA Is Signed, Not That White House Wanted Anyone To Notice
Generic User Fee Agreement Includes FDA Pledge To Determine Best Use Of Foreign Regulator Inspections
Advertisement
UsernamePublicRestriction

Register

PS000716

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel